key: cord-0958970-q8qo280x
authors: Mahajan, Aditi; Bhattacharyya, Shalmoli
title: Application of Mesenchymal stem celland secretome for combating mortality and morbidity in COVID-19patients: A brief review
date: 2020-09-28
journal: Biomed J
DOI: 10.1016/j.bj.2020.09.003
sha: 8acad194b9a90fb53744087cdf1252624711534b
doc_id: 958970
cord_uid: q8qo280x

Coronavirus disease 2019 (COVID-19) caused by novel Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV2), is typically associated with severe respiratory distress and has claimed more than 525,000 lives already. The most fearful aspect is the unavailability of any concrete guidelines and treatment or protective strategies for reducing mortality or morbidity caused by this virus. Repurposing of drugs, antivirals, convalescent plasma and neutralizing antibodies are being considered for treatment but are still questionable in lieu of the conflicting data, study design and induction of secondary infections. Stem cell therapy has seen substantial advancements over the past decade for the treatment of various diseases including pulmonary disorders with severe complications similar to COVID-19. Recently, mesenchymal stem cells (MSCs) have received particular attention as a potential therapeutic modality for SARS-CoV2 infection due to their ability to inhibit cytokine storm, a hallmark of severe COVID-19. MSCs secretion of trophic factors and extracellular vesicles mediated intercellular signaling are considered as principal contributing factors for tissue recovery. Although, recent preliminary studies have established the safety and efficacy of these cells without any severe secondary complications in the treatment of SARS-CoV2 infection, the rational use of MSCs on a large scale would still require additional relevant clinical investigations and validation of postulated mechanisms of these cells. This review presents the current clinical findings and update on the potential use of stem cell therapy and its secretome in combating the symptoms associated with COVID-19.

A number of antiviral drugs [3] , corticosteroids [4] , convalescent plasma [5] and neutralizing monoclonal antibodies [6] are being tested and are in different phases of clinical trial but none has specifically been approved for COVID-19.Another alarming development is the report from some of the countries about recurrence of the infection in recovered individuals, thus, questioning the efficacy of available treatments [7] . Vaccine development is underway on war footing, but the complete process of safety evaluation, manufacturing and scale up may still take some more time. As such, the need of the hour is to look for immediately available therapies that may be utilized in combating the COVID-19 infections.

Mesenchymal stem cells (MSCs) have long been associated with the repair and rejuvenation of damaged tissues owing to their broad pharmacological effects including anti-inflammation, immunomodulation, anti-apoptosis, angiogenesis and trans-differentiation to specific cell types. They also secrete a myriad of soluble factors and vesicles that are altogether involved in restoring the tissue homeostasis and functionality. The efficacy of MSCs and their secretory factors has been proven in reducing inflammation and dampening immune responses as well as repairing lung damage in various pre-clinical and clinical models.

Therefore, the potential of MSC based therapy as an option for severe or critically ill COVID-19 patients is being explored in the current scenario. This review summarizes the clinical use of MSCs and their secretory products and points out their common mechanisms of action in mitigating the current battle against COVID-19.

stranded positive sense RNA viruses with a genome size of 29.9 kb. These viruses are categorized into four sub-families-α, β, γ and δ. Of these, only α and β viruses are capable of causing human infections. The two types of coronaviruses earlier reported-SARS and MERS belong to the βfamily. COVID-19 also belongs to the βfamily, and shares 79.5 % similarity with SARS and 50 % similarity with MERS coronaviruses [9] . The nucleocapsid of the virion consists of RNA genome complexed with nucleoprotein, and is enveloped by phospholipid bilayer. This bilayer is covered with two types of spike proteins-S protein which is present on all known coronaviruses and forms peplomers on the surface giving it a solar corona like appearance, and hemeagglutinin esterase (HE) protein which is present on only a few types of coronaviruses. The spike S protein interacts with the host angiotensin converting enzyme 2 (ACE2) receptor protein whichresults in either membrane fusion with subsequent release of viral genome into the cell, or in clathrin dependent and independent endocytosis of the virus [10] . ACE2 receptor is widely expressed by human cells, particularly in the lungs by alveolar type II (AT2) cells and capillary epithelial cells, and the cells of the heart, kidney and intestine. Additionally, two proteases-transmembrane serine protease 2 (TMPRSS2) and extracellular matrix metalloproteinase inhibitor (EMMPRIN or CD147) have also been reported to be essential for virus entry into the host cell [11] . The damage to the lungs is caused by the virus either directly-by destruction of AT2 and capillary endothelial cells, which disrupts the renin-angiotensin system, or indirectly by dampening of the immune response [9] . The exact pathogenesis of the particular virus still remains unknown. Most of the information regarding the infection cycle and the consequent immune response is largely derived from SARS and MERS coronaviruses because of the correlation in the clinical features of COVID-19 patients with these virus infections [12, 13] . Once the virus has established the infection, it is recognized by innate immune system via pathogen associated molecular patterns (PAMPs) which in this case is the virion genomic RNA. This leads to the activation of NFκB pathway and IRF3 pathway, which in turn results in the expression of type I interferon (IFN). IFN then activates the JAK/STAT pathway, and induces the expression of IFN stimulated genes (ISG) which have anti-viral activity [14] . The successful clearance of the virus and improvement in the clinical manifestations of the disease is dependent on this effective immune response. However, the virus can evade IFN and ISG mediated killing, and often results in a delayed IFN response. This causes infiltration of hyper-inflammatory neutrophils and macrophages at the pulmonary site, along with proinflammatory cytokines mainly, IL-1β, IL-2, IL-6, IL-7, IL-8, IL-17, G-CSF, GM-CSF, CCL3, MCP1 and TNF [15] . This so called 'cytokine storm' as a result of innate response J o u r n a l P r e -p r o o f (neutrophils and macrophages) as well as hyper-activation of T-lymphocytes (particularly Th1 response) is actually responsible for the lung dysfunction and abnormalities like pneumonitis, ARDS, respiratory failure, viral sepsis and organ failure (figure 1). High levels of pro-inflammatory cytokines also induce synthesis of hyaluronan synthase 2, which produces hyaluronan in the lungs, causing the characteristic 'ground glass' opacity or fluid accumulation in the lungs [16] . In critically ill cases, the virus is also able to enter the peripheral blood (viremia) and be translocated to its other target organs expressing ACE2 receptor, such as heart, kidney and intestines resulting in multiple organ dysfunctions.

There is no specific therapy or vaccine available to fight COVID-19. This has compelled the healthcare workers to use drugs on compassionate use, based on the previous outbreaks of which involve isolation of the patient to a negative pressure room, nutritional and electrolyte management and hydration in combination with antibiotics and antiviral agents, which work only in cases of mild or moderate symptomatic patients, while critically ill require additional support in terms of invasive ventilation, extracorporeal membrane oxygenation and multiorgan functional therapies. Although no specific antiviral agents have been approved for the disease management, a few were found effective during previous outbreaks of SARS-CoV and MERS-CoV, which include ribavirin, lopinavir/ritonavir, remdesivir and cholorquine and its -hydroxy derivative. Lopinavir/ritonavir which are HIV protease inhibitors, were successfully used in the case of an index patient who caused tertiary transmission in Korea.

The patient was administered 200 mg lopinavir and 50 mg ritonavir orally at day 10 of illness, and was found to be recovering since then [17] . However, other studies have reported that the use of these drugs do not exert any benefit in terms of shortening time period of virus shedding and mortality rate in comparison to the standard care group, and even lead to gastrointestinal complications [18, 19] . Remdesivir is a nucleoside analog which can inhibit SARS-CoV2 replication in pulmonary epithelial cells. The first case of COVID-19 in United

States was treated with remdesivir intravenously from day 6 of the admission to the hospital, following which the clinical symptoms improved with an increase in the oxygen saturation.

However, the improvement in the clinical outcome of the patient cannot be conclusively J o u r n a l P r e -p r o o f accredited to remdesivir, as the virus is self-limiting and the improvement could possibly be because of self-defense mechanism and supportive treatments [20] . Quinine derivatives such as chloroquine and hydroxychloroquine which are in use as anti-malarial drugs, have also been tested for their efficacy in the treatment of COVID- 19 . In an open label, nonrandomized clinical trial, it was shown that the use of hydroxychloroquine and azithromycin combination was associated with the reduction in viral load and complete cure within 3-6 days of treatment in comparison to the control group [21] . However, some other studies have reported no significant differences in the clearance of the virus or disease course with the administration of hydroxychloroquine [22, 23] . Inconclusive and conflicting data in addition to the adverse reactions such as cardiac arrhythemias, ventricular tachychardia [24] , multiorgan complications like renal failure, liver injury and gastroinstestinal disorders [25] question the exact efficacy and safety of these drugs and therefore warrant further research, testing and more clinical trials before the adoption of such therapies on a larger scale. Earlier, the use of convalescent plasma or passive antibody treatment has been found effective in various viral infections including SARS-CoV, MERS-CoV, Ebola, H5N1 influenza and H1N1 influenza and therefore it was now tested for SARS-CoV2 [26] . A preliminary study in China had reported treatment of five critically ill patients using plasma from recovered patients. Concomitant with anti-viral treatment, all these patients had received plasma transfusion on day 10, which significantly improved the clinical status of patients including their body temperature normalization, decrease in sequential organ failure assessment and viral load. Although the success of these cases is compelling, the study suffers a major limitation in that the patients receiving convalescent plasma were not compared to those not receiving the treatment, thus making it impossible to truly contemplate the role of convalescent plasma in the clinical outcome of the patients [5] . The use of corticosteroids has also been reported to suppress the hyperactive immune response against the virus, but the safety and efficacy of such treatment is still controversial due to the delayed clearance of viral infection and potential risk of secondary complications [4] . Immunotherapy using monoclonal antibodies are also in the clinical pipeline to combat COVID-19. A monoclonal antibody Tocilizumab against the IL-6 receptor interferes with IL-6 binding and resultant cytokine storm and is currently being investigated for COVID-19. In a retrospective analysis of 21 severe or critically ill patients, 400 mg Tocilizumab was administered via intravenous drip, which resulted in normalization of the body temperature within 1 day, and a remarkable increase in peripheral oxygen saturation along with improvement in other clinical features in the following days. Percentage of lymphocytes and C-reactive protein were returned to J o u r n a l P r e -p r o o f normal range within 5 days of treatment [27] . Different potential treatment options are also being proposed that can also be pursued as therapy for SARS-CoV2. These include neutralizing antibodies against spike S protein of the virus to block viral entry and spread [28] and CD147 receptor on host cells [29] , drugs that block virus endocytosis into the host cell such as Baricitinib, and JAK/STAT signaling inhibitors to suppress inflammatory responses [30] . Most of these strategies are still at nascent stage and require extensive testing in vitro and in vivo before these can ladder up to clinical trials.

Another strategy that is being used since decades for numerous diseases and disorders and The key to an effective treatment for COVID-19 is to employ a strategy that not only prevents virus shedding, but also suppresses the hyperactive immune response at the same time to restore the normal functioning of the lungs. MSCs are proven to be anti-viral and antibacterial due to secretion of various anti-pathogenic proteins, and can also suppress the cytokine storm due to their characteristic anti-inflammatory and immunomodulatory properties. and IFN-γ causing lung edema and leading to ARDS. In a study, administration of MSCs in a murine model of ALI resulted in complete attenuation of neutrophils and generation of a potent anti-inflammatory response mediated by secretion of anti-inflammatory molecules and a shift in Th1 to Th2 response [32] . MSCs also express high levels of Leukemia inhibitory factor (LIF) which plays an important role in controlling the cytokine storm. Laboratory developed stem cells are available as 'LIFNano' which have 1000 times more potency than soluble LIF. This novel emerging therapy for autoimmune diseases, may also be beneficial in the management of virus induced pneumonia by reducing hyper-inflammation in the lungs [33] . MSC based therapy has also shown promising results for the treatment of ARDS, with several preclinical models depicting the attenuation of inflammatory status of the lungs with MSCs infusion, secretion of antimicrobial peptides and proteins such as lipocalin to promote bacterial clearance, secretion of keratinocyte growth factor to promote fluid clearance and reepithelialization of the lung alveoli [34, 35] . MSCs also restore the metabolic capacity of alveolar cells, including alveolar macrophages by direct transfer of their functional mitochondria which results in their polarization from M1 phenotype (inflammatory) to M2 phenotype (anti-inflammatory) [36] . MSCs provide significant protection against oxidative stress associated with lung inflammation due to the expression of high levels of antioxidant enzymes such as catalase, superoxide dismutase and glutathione peroxidases. In addition to reducing inflammation, MSCs induce regeneration of lung epithelium by differentiating into type II cells, and partly due to paracrine effects resulting in decreased apoptosis of alveolar cells, as depicted in a rat model of emphysema [37] . Destruction of alveolar epithelial cells and type II pneumocytes is also seen during CoV2 infection. MSCs express high levels of ISG (IFITM, IFI6, ISG15, SAT1, PMAP1 and CCL2) which possess antiviral activity and have been proven to mitigate virus induced respiratory ailments [38] . In a clinical trial, [40] . Some studies also suggest the use of 'licensing approach', which involves a pre-treatment of MSCs with IFN-γ or TNF-α to stimulate their anti-inflammatory properties. Such pre-conditioned MSCs would have higher effective in clearing the immune response and promotion of lung tissue repair [16, 41] .

MSCs based immunomodulation operates through a synergy of cell contact dependent as well as independent mechanisms (via soluble factors/secretome). Therefore, both systemic and local delivery of MSCs to inflamed lungs should result in induction of anti-inflammation by these cells.

It has been proven over the recent years that the central mode of action of MSCs for providing the actual therapeutic benefit resides in their paracrine activity, i.e., the release of soluble factors. These molecules include transcription factors, growth factors, angiogenic molecules, lipid mediators, nucleic acids, cytokines, chemokines, hormones and extracellular vesicles, which are collectively termed as the secretome of stem cells. The secretome serves a wide array of biological functions, which include cell survival and proliferation, antiapoptosis, cell contractility, migration, angiogenesis, anti-inflammation, immunomodulation and homing of resident stem cells, thus contributing to the tissue refurbishment and functional recovery [42] . Secretome therapy has also emerged as a promising cell free 'ready to go' therapeutic tool with active release biological substances for several acute and chronic mRNA and miRNAs to target cells. This mode of intercellular signaling via transport of functional cargo by MSCs derived EVs has gained immense biological significance for their ability to regulate the recipient cells during pathophysiological conditions. These EVs also transport functional mitochondria to the alveolar cells to restore their metabolic capacity. The key events during virus infection can also be regulated by the shuttling of miRNAs such as miR-30b-3p [45] and miR-146a [46] which reduce inflammation and miR-21-5p which interferes with oxidative stress induced apoptosis [47] . This way, MSCs can not only be used directly but also in the form of 'cell free' approach utilizing only the secreted mediators for alleviating CoV2 infection.

A pilot study carried out in China reported the first clinical use of umbilical cord derived MSCs (UC-MSCs) for the treatment of a 65 year old female infected with SARS-CoV2 [48] .

The patient was admitted to the hospital on January 27, 2020 and displayed the early clinical symptoms of COVID-19 such as fatigue, high body temperature and cough with production of sputum. Chest radiograph displayed ground glass opacity in the lungs, and qRT-PCR test confirmed the virus positivity the next day. The condition of the patient deteriorated in the subsequent days following which she was treated with antiviral drugs and IFN-α inhalation, methylprednisolone, and antibiotics along with non-invasive mechanical ventilator. However, glucocorticoid and antiviral therapy was withdrawn after 10 days because of the extreme side effects. The patient condition was re-evaluated and was found to be critically ill with severe pneumonia and ARDS, multi-organ failure syndrome, moderate anemia, hypertension, 19 . In yet another case, a 54 year old man positive for CoV2 was presented with chest tightness, shortness of breath, decreased oxygen saturation values, ground glass opacity in the lungs and pneumonia. Initially, the patient was treated with lopinavir/ritonavir but considering the severe organ injury due to inflammatory attack, he was then treated with 1 * 10 6 UC-MSCs per kg body weight. After MSCs infusion, the clinical symptoms improved, along with marked increase in total lymphocyte count and decrease in CRP levels and inflammatory markers. The patient was tested negative for CoV2 after 6 days of infusion [49] . In another preliminary clinical trial, 7 patients were treated with a single infusion of 1 x 10 6 clinical grade MSCs per kg of body weight [40] . These MSCs were found to be safe, as indicated by absence of any acute allergic reaction, or even delayed (table 1) . Additionally, two more registered trials will be exploring the efficacy of inhaled MSCs derived EVs in mitigating the SARS-CoV2 induced respiratory and other defects. Nonetheless, the estimated recruitments in most of these trials is quite low (<50), and additional data may still be required before the successful adoption of stem cells for the management of this pandemic. The clinical results would need to be repeated in larger and well controlled trials to fully ascertain the safety as well as therapeutic potency of MSCs and their secretory products. Not only this, the route of administration as well as the dosage need to be optimized as these affect the final therapeutic outcome. One study has reported intravenous (IV) route as a better option in comparison to intratracheal (IT) route using a preclinical emphysema model [51] , another has reported equivalent efficacy of MSCs via endobronchial as well as IV route for ARDS [52] . Though both systemic and local administration of MSCs in various lung inflammatory disorders have proven to be effective [53] , a comparative efficacy of different routes of MSCs delivery to the lungs is yet to be defined. As such, there is no definitive route that can be considered safest and most effective for treatment of COVID-19. Most of the clinical trials registered till date have opted for IV application of MSCs and intranasal route for exosomes delivery. Intranasal route via inhalation is an under-explored research area, but is reported to be more efficient for the direct delivery of MSCs with lower risks for adverse reactions [54] . Nonetheless, MSCs accumulate first in the hyper-inflammatory lungs owing to their tropism for inflamed regions, irrespective of the route of administration, thus making them desirable for treatment of both acute and chronic lung disorders. More than 80 percent of MSCs are trapped in the lungs within a few minutes of their infusion via IV route, where these exert their anti-inflammatory effects in response to the inflammatory cytokines present in the lungs. In case of secretome or EVs, local delivery seems to be a more sustainable option, as systemic flow often results in significant loss in the infused cell free products, thus calling for booster dosages. Local infusion of secretome and/or exosomes also results in rapid onset of action, and also requires lower dosages to achieve the same therapeutic effect [55] . While IV injections have been reported to deliver exosomes/secretome to spleen and liver first, followed by lungs, there aren't any reports till date depicting the biodistribution as well as metabolic fate of these cell free products following local delivery. Even so, intravenous injections of MSCs products have been reported to be therapeutically effective. In fact, in an open label cohort study, exosomes derived from allogenic bone marrow stem cells were infused intravenously in a total of 24 patients with severe COVID-19 showing moderate to severe ARDS [56] . The preliminary findings of this clinical trial proved that intravenous exosomes infusions were safe, and did not result in any adverse events. It improved the overall clinical outcomes with a success rate of approximate 80 percent. Apart from this, dosage strategies including number of cells/EVs per infusion and total number of infusions are equally important. Based on the previous clinical trials, it is estimated that a patient requires around 4oo million cells regardless of the clinical indication [57] . Even in the registered clinical trials for COVID-19, approximately 1-10 * 10 6 MSCs per kg of body weight are given to the patients, with an average of 3 booster doses [50] . However, the exact dose for every patient needs to be optimized, as it may vary depending on the tolerability, safety and efficacy in different patients. Obviously, higher doses of MSCs are also associated with both biological and nonbiological issues such as risks of emboli formation and neoplasm transformation, uncontrolled cell proliferation and differentiation in the body and higher manufacturing and maintenance costs, which impose major restrictions on their use at larger scales. In case of cell free products, the approximate number of MSCs required to produce enough secretome is J o u r n a l P r e -p r o o f 13 generally 5-10 times higher to achieve the same therapeutic effect, which necessitates large scale production under the strict compliance of good manufacturing practices (GMP) [55] .

Furthermore, inclusion and exclusion criteria of patients, co-infections and co-morbidities, source of MSCs, dosing strategies, and laboratory preparations and manipulations would also be required to be evaluated and optimized in a comprehensive manner.

The global pandemic of COVID-19 calls for urgent development of therapeutic strategies that could be readily available. Even with the availability of current 'repurposed' therapies, the mortality rate is still high. Cellular therapy against COVID-19 involves the use of allogenic 

This study did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. 

Remdesivir for Patients with Severe Covid-19

low-dose and shortterm application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan

Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma

Allergy and Immunology Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19)

Positive RT-PCR Test Results in Patients Recovered from COVID-19

Severe acute respiratory syndrome-related coronavirus: The species and its viruses-a statement of the Coronavirus Study Group

Virology, epidemiology, pathogenesis, and control of covid-19

Molecular immune pathogenesis and diagnosis of COVID-19

Emerging coronaviruses: Genome structure, replication, and pathogenesis

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic

COVID-19: immunopathology and its implications for therapy

COVID-19 infection: the perspectives on immune responses

Case of the index patient who caused tertiary transmission of coronavirus disease 2019 in Korea: The application of lopinavir/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan

First case of 2019 novel coronavirus in the United States

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19

A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)

Response to the editorial "COVID-19 in patients with cardiovascular diseases

Incidence of Adverse Drug Reactions in COVID-19 patients in China: an active monitoring study by Hospital Pharmacovigilance System

Convalescent Plasma to Treat COVID-19: Possibilities and Challenges

Effective Treatment of Severe COVID-19 Patients with Tocilizumab

Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China

CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement

COVID-19: combining antiviral and anti-inflammatory treatments

Mesenchymal stem cells and inflammatory lung diseases

Mesenchymal stem cells and management of COVID-19 pneumonia

Concise review: Mesenchymal stromal cell-based approaches for the treatment of acute respiratory distress and sepsis syndromes

Mesenchymal stem cell-derived extracellular vesicles for the treatment of acute respiratory distress syndrome

Mesenchymal Stromal Cells Modulate Macrophages in Clinically Relevant Lung Injury Models by Extracellular Vesicle Mitochondrial Transfer

Mesenchymal stem cells transplantation protects against rat pulmonary emphysema

Current Status of Cell-Based Therapies for Respiratory Virus Infections: Applicability to COVID-19

Clinical Study of Mesenchymal Stem Cell Treatment for Acute Respiratory Distress Syndrome Induced by Epidemic Influenza A (H7N9) Infection: A Hint for COVID-19 Treatment

Transplantation of ACE2-Mesenchymal stem cells improves the outcome of patients with covid-19 pneumonia

Mesenchymal Stem Cells: a Potential Novel Therapeutic for COVID19 Patients

Mesenchymal Stromal Cell Secretome for Severe COVID-19 Infections: Premises for the Therapeutic Use

The Immunomodulatory Functions of Mesenchymal Stromal/Stem Cells Mediated via Paracrine Activity

Anti-inflammatory effects of mesenchymal stem cells: Novel concept for future therapies

Exosomes derived from microRNA-30b-3p-overexpressing mesenchymal stem cells protect against lipopolysaccharide-induced acute lung injury by inhibiting SAA3

Exosomal miR-146a Contributes to the Enhanced Therapeutic Efficacy of Interleukin-1β-Primed Mesenchymal Stem Cells Against Sepsis

Mesenchymal stromal cells-derived exosomes alleviate ischemia/reperfusion injury in mouse lung by transporting anti-apoptotic miR-21-5p

Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells

Intravenous infusion of human umbilical cord Wharton's jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia

Effects of different mesenchymal stromal cell sources and delivery routes in

Cell therapy for ARDS: Efficacy of endobronchial versus intravenous administration and biodistribution of MAPCs in a large animal model

MSC Based Therapies-New Perspectives for the Injured Lung

Can Stem Cells Beat COVID-19: Advancing Stem Cells and Extracellular Vesicles Toward Mainstream Medicine for Lung Injuries Associated With SARS-CoV-2 Infections

Could Mesenchymal Stem Cell-Derived Exosomes Be a Therapeutic Option for Critically Ill COVID-19 Patients?

Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19

Peak MSC-Are We There Yet?